A virtual, connected community in drug repurposing to foster collaboration, networking and knowledge transfer:

A new era for Drug Repurposing

Mechanism-based drug repurposing is a new approach that will change how we think about medicine. It will help find new uses for drugs that are already registered, increase precision and reduce costs and time in the drug development process. This shift in thinking will make it easier to transition to clinical trials that are fit-for-purpose, innovation-driven and compliant with the highest standards in safety and operational excellence.

Discovery and repurposing face a common challenge of imprecise treatment of diseases due to a lack of mechanistic understanding. Our team of leading scientists has made significant advancements in the field of bioinformatics and artificial intelligence, leveraging big data to redefine diseases based on their underlying mechanisms. Although patients are still diagnosed based on symptoms, our approach stratifies them according to the endotype, i.e., the causal mechanism behind their illness.

In five years, REPO4EU will establish an innovative web-based platform for drug repurposing for high unmet medical need indications to European researchers and SMEs with an Open Science concept.

AI-POWERED

Digital biomarkers and AI models for patient stratification

PRIVACY-BY-DESIGN

Ethics & data protection, patents, freedom to operate & a global HTA database

2D & 3D PRINTING

GMP-compliant repurposing at any dose

INNOVATION-DRIVEN

Advocating for safety-first, excellence-driven phase I/II clinical trials

The Role of Egnosis

RePo4EU is the collective vision of a group of established collaborators in the field of innovative drug repurposing, aimed at creating a comprehensive European/global platform that enables validated precision drug repurposing. This platform will be open to stakeholders, providing access to information, multimedia training, matchmaking, and cooperation opportunities.

Egnosis, with its 14+ years of proven expertise in market-validated software development, serves as a bridge between science and industry, further empowering RePo4EU. In this purposeful project, we play a role in the definition of the:

  • Stakeholders’ requirements specification,
  • The architecture of the platform,
  • The complete software development lifecycle,
  • The implementation of the interconnections with publication systems and the development of the sustainability plan.

“A highly professional and fast delivering team on complex web-based programming needs. We worked nicely in the Horizon 2020 project REPO-TRIAL and will now expand this in the European platform project REPO4EU.”

Prof. Dr. Med. Harald H.H.W. Schmidt

Start date
01 September 2022

Duration
7 years

Participants
28 institutions from 10 countries

Horizon Europe Funding
€22.98 million

Egnosis’ Budget
€970,625

 

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101057619

 

News and publications

Stay up-to-date with the latest news, articles, and publications by visiting the official website here.

Click here to access the complete newsletter and subscribe to stay informed!

 

 

This project is funded by the European Union under grant agreement No. 101057619. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

Source: https://repo4.eu/